ReportGemReportGem 中文

PUBLIC COMPANY RESEARCH HUB

1093.HK (1093.HK) Foreign Research Coverage

A focused collection of foreign research coverage for 1093.HK, organized by institution and publication date for faster discovery.

Evidence documents3
Filings0
Meetings0
Research3
Displayed research share100%
Latest evidence2026-08-20

Foreign research

Quick Take: CSPC 2Q26 a solid beat on sales and licensing; mRNA strategy under the spotlight2026-08-20 · Bernstein

20 August 2026 Rebecca Liang, Ph.D. China Pharma and Biotech CSPC Pharmaceutical Group Ltd Ellie Li Rating Market-Perform Price Target 1093.HK 10.70 HKD Quick Take: CSPC 2Q26 a solid beat on sales and licensing; mRNA strategy under the spotlight …

Risk Reward Update2026-08-20 · Morgan Stanley

Not for redistribution without written consent of Morgan Stanley M Update August 20, 2026 01:36 PM GMT Morgan Stanley Asia Limited+ CSPC Pharmaceutical Group | Asia Pacific Alexis Yan, CFA Equity Analyst Risk Reward Update What’s Changed …

Takeaways from 2Q26 Earnings Call - Focus on mRNA Vaccine and AIDD2026-08-20 · Morgan Stanley

Questions this evidence can help answer

  • What changed in the latest research coverage of 1093.HK?
  • Which operating and valuation themes recur across institutions?
  • Which claims should be checked against company primary-source evidence?
Research this company with AI